PACAP Peptide Is Essential for Nerve Pain — Mice Without It Don't Develop Neuropathic Hyperalgesia
PACAP-deficient mice failed to develop neuropathic pain after nerve injury, while tachykinin-deficient mice still developed pain normally, identifying PACAP as a critical mediator of neuropathic hyperalgesia.
Quick Facts
What This Study Found
Using partial sciatic nerve ligation in gene-deficient mice:
- PACAP(-/-) mice: Did NOT develop mechanical hyperalgesia (30-40% in wildtype), identifying PACAP as crucial for neuropathic pain
- Tac1(-/-) mice (lacking SP/NKA): Developed hyperalgesia normally — tachykinins are NOT required for neuropathic pain
- Tacr1(-/-) mice (lacking NK1 receptor): Also developed hyperalgesia normally
- Motor coordination: Impaired in both PACAP(-/-) and Tac1(-/-) mice, unaffected in Tacr1(-/-)
- Basal skin blood flow: Reduced in Tac1(-/-) and Tacr1(-/-), normal in PACAP(-/-)
- Neurogenic vasodilation (mustard oil): Significantly reduced in PACAP(-/-), normal in Tac1(-/-) and Tacr1(-/-)
Conclusion: PACAP and tachykinins have distinct, non-overlapping roles in pain, vascular regulation, and motor function.
Key Numbers
How They Did This
Gene-deficient (knockout) mice for PACAP, Tac1 (substance P/NKA), and Tacr1 (NK1 receptor) underwent partial sciatic nerve ligation to model neuropathic pain. Mechanical pain threshold was measured with dynamic plantar aesthesiometry, motor coordination with Rota-Rod, and skin blood flow with laser Doppler imaging. Neurogenic vasodilation was tested with mustard oil stimulation.
Why This Research Matters
Neuropathic pain affects millions and is notoriously difficult to treat. Identifying PACAP as a crucial mediator — when substance P (long thought to be the key pain peptide) turned out not to be required — fundamentally shifts the drug target landscape. Developing PACAP antagonists could open new treatment approaches for chronic nerve pain.
The Bigger Picture
For decades, substance P was considered the primary pain neuropeptide, leading to the development of NK1 receptor antagonists for pain — which largely failed in clinical trials. This study helps explain why: PACAP, not substance P, is the critical mediator of neuropathic pain. This redirection of drug development targets could lead to more effective neuropathic pain treatments.
What This Study Doesn't Tell Us
Mouse models of neuropathic pain may not fully recapitulate human conditions. Compensatory mechanisms in knockout mice could mask or exaggerate the roles of individual peptides. Only one model of neuropathic pain (partial sciatic nerve ligation) was tested. The downstream targets of PACAP mediating neuropathic pain were not identified in this study.
Questions This Raises
- ?Which PACAP receptor subtype (PAC1, VPAC1, or VPAC2) mediates the neuropathic pain effect?
- ?Would PACAP antagonists effectively treat neuropathic pain in humans?
- ?Does PACAP play the same critical role in other types of chronic pain beyond traumatic neuropathy?
Trust & Context
- Key Stat:
- No hyperalgesia in PACAP-knockouts While wildtype mice developed 30-40% mechanical hyperalgesia after nerve ligation, PACAP-deficient mice showed no pain hypersensitivity — substance P-deficient mice developed pain normally
- Evidence Grade:
- This is a well-designed preclinical study using three gene-knockout mouse lines with multiple functional assessments. The clear dissociation between PACAP and tachykinin roles provides strong mechanistic evidence, though results need human validation.
- Study Age:
- Published in 2013, this study was among the early demonstrations of PACAP's crucial role in neuropathic pain. PACAP has since become a recognized drug target, with antagonists in early development.
- Original Title:
- Role of Pituitary Adenylate-Cyclase Activating Polypeptide and Tac1 gene derived tachykinins in sensory, motor and vascular functions under normal and neuropathic conditions.
- Published In:
- Peptides, 43, 105-12 (2013)
- Authors:
- Botz, Bálint, Imreh, András, Sándor, Katalin, Elekes, Krisztián, Szolcsányi, János, Reglődi, Dóra, Quinn, John P, Stewart, James, Zimmer, Andreas, Hashimoto, Hitoshi, Helyes, Zsuzsanna
- Database ID:
- RPEP-02134
Evidence Hierarchy
Frequently Asked Questions
What is PACAP and why is it important for pain?
PACAP (pituitary adenylate cyclase-activating polypeptide) is a neuropeptide found in sensory nerves. This study showed it's essential for developing neuropathic pain — mice without it simply don't develop the pain hypersensitivity that normally follows nerve injury. This makes PACAP a promising new drug target for chronic pain conditions that don't respond well to current treatments.
Why did substance P turn out not to be needed for nerve pain?
Despite decades of research on substance P as a pain peptide, mice lacking substance P still developed neuropathic pain normally in this study. This helps explain why NK1 receptor antagonists (substance P blockers) failed in clinical trials for pain — they were targeting the wrong peptide. PACAP, not substance P, appears to be the critical driver of neuropathic pain.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02134APA
Botz, Bálint; Imreh, András; Sándor, Katalin; Elekes, Krisztián; Szolcsányi, János; Reglődi, Dóra; Quinn, John P; Stewart, James; Zimmer, Andreas; Hashimoto, Hitoshi; Helyes, Zsuzsanna. (2013). Role of Pituitary Adenylate-Cyclase Activating Polypeptide and Tac1 gene derived tachykinins in sensory, motor and vascular functions under normal and neuropathic conditions.. Peptides, 43, 105-12. https://doi.org/10.1016/j.peptides.2013.03.003
MLA
Botz, Bálint, et al. "Role of Pituitary Adenylate-Cyclase Activating Polypeptide and Tac1 gene derived tachykinins in sensory, motor and vascular functions under normal and neuropathic conditions.." Peptides, 2013. https://doi.org/10.1016/j.peptides.2013.03.003
RethinkPeptides
RethinkPeptides Research Database. "Role of Pituitary Adenylate-Cyclase Activating Polypeptide a..." RPEP-02134. Retrieved from https://rethinkpeptides.com/research/botz-2013-role-of-pituitary-adenylatecyclase
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.